| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/13/2004 | US20040092480 Factor x inhibitors; antocoagulants; thrombosis therapy; diphenylamidine compound in binder |
| 05/13/2004 | US20040092470 Dry powder oligonucleotide formualtion, preparation and its uses |
| 05/13/2004 | US20040092452 Adding formulation to dissolution medium having osmolarity of 100-550 mOsmol/L and ph of 7-12, maintaining at 0-50 degrees above glass transition temperature of polylactide and determining amount of peptide in the sample |
| 05/13/2004 | US20040092435 Treatment of ocular disease |
| 05/13/2004 | US20040092428 Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof |
| 05/13/2004 | US20040091702 Storage wrap material |
| 05/13/2004 | US20040091579 Adding a quantity of an active selected from the group consisting of vitamins, vitamin precursors, drugs and mixtures to starting formulation and passing into and through an elongated extruder barrel to cook |
| 05/13/2004 | US20040091559 Compositions for diabetes treatment and prophylaxis |
| 05/13/2004 | US20040091555 Methods for producing agrimonia extracts with improved activity against hepatitis b virus and pharmaceutical and food compositions containing said extracts |
| 05/13/2004 | US20040091546 Made of amphiphilic copolymers at a predictable/controlled size and yield; mixing a solution of an amphiphilic copolymer in a process solvent with a non-process solvent; flash precipitation in a product solvent; solubility; stability |
| 05/13/2004 | US20040091545 Entrapping the acid in a methacrylic acid copolymer by acidifying a basic solution or dispersion to cause formation of a precipitate which is then collected and dried; odorless dietary supplement for cardio-vascular systems |
| 05/13/2004 | US20040091544 Applying a solution of the active pharmaceutical ingredient, e.g. a peptide such as insulin, to form a coating on a particulate substrate which is free of a polysaccharide; permeation promoter coating to control release; capsules |
| 05/13/2004 | US20040091543 Embolic compositions |
| 05/13/2004 | US20040091542 Method for the preparation of nanoparticles |
| 05/13/2004 | US20040091541 Solid matrix therapeutic compositions |
| 05/13/2004 | US20040091538 Dosage form providing ascending release of liquid formulation |
| 05/13/2004 | US20040091537 Non-digestible sugar-coated products and process |
| 05/13/2004 | US20040091536 Stability of masking of the taste when the reconstitutable, dry suspension contains granules having a core of drug and excipients (thickener, preservative and buffer) and at least three successive layers of coating; organoleptic |
| 05/13/2004 | US20040091535 Coated tablets |
| 05/13/2004 | US20040091534 Once-daily administrations characterised by a high degree of absorption using pellets comprising a powder mixture of drug, acid/base excipients and diluent surrounded by a multilayer membrane of water soluble and insoluble polymers to control |
| 05/13/2004 | US20040091533 A safe and effective twelve to twenty-four hour formulation comprising a decongestant core which has a delay release coating and an immediate release coating of both drugs, a water soluble binder and surfactant; one-a-day orally |
| 05/13/2004 | US20040091532 One-a-day, oral administration of a methylphenidate drug, e,g, Ritalin, the dosage of which form provides an immediate dose upon ingestion followed by release of more dose(s) later; particles uncoated/coated with ammonio methacrylate |
| 05/13/2004 | US20040091531 Modified release of an insulin sensitizer and a pharmaceutically acceptable carrier; sustained release; time-release agents; pulsation; enteric tablets; hypoglycemic agents, pioglitazone or troglitazone; Type 2 diabetes |
| 05/13/2004 | US20040091530 Dosage forms for oral admistration resulting in a maximum secretagogue plasma concentration, Cmax, less than 80% Cmax of that when an equal dose is administered in an immediate release form; osmotic tablet of a asymetric membrane; 6 hours |
| 05/13/2004 | US20040091529 Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
| 05/13/2004 | US20040091528 Soluble drug extended release system |
| 05/13/2004 | US20040091526 A graphic art marking of a pregnant women, is used to prevent erroneous dispensing of or erroneous ingestion of drugs not intended for pregnant women, improve patient compliance, product effectiveness |
| 05/13/2004 | US20040091525 Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitor component |
| 05/13/2004 | US20040091523 Pharmaceutical composition and the process for its preparation |
| 05/13/2004 | US20040091522 Lipid microparticles by cryogenic micronization |
| 05/13/2004 | US20040091521 Multilayer backing construction for active substance patch systems |
| 05/13/2004 | US20040091516 Printing or dispensing a suspension such as three-dimensional printing of dosage forms |
| 05/13/2004 | US20040091462 Composition for the carrying and delivery of bone growth inducing material and methods for producing and applying the composition |
| 05/13/2004 | US20040091443 Conditioning polymer encapsulated in lipid vesicle |
| 05/13/2004 | US20040091433 Chromene derivative |
| 05/13/2004 | US20040091432 Oral hygiene system and method of treatment |
| 05/13/2004 | US20040091425 Polyvinyl alcohol microspheres, and methods for making and therapeutic uses of the same |
| 05/13/2004 | US20040091423 Methods for identifying asymptomatic patients who have a likelihood of benefiting from administration of an estrogen activity modulator for risk reduction or therapeutic treatment of breast cancer, methods for reducing risk or |
| 05/13/2004 | US20040091407 Novel process for preparing crystalline particles of a salt of a substance, particularly particles of therapeutically useful or carrier substances of a size suitable for inhalation therapy. |
| 05/13/2004 | US20040089753 Wet milling process |
| 05/13/2004 | US20040089293 Medicament dispenser |
| 05/13/2004 | US20040089290 Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume |
| 05/13/2004 | DE10251256A1 Transdermales Wirkstoffabgabesystem für Oxybutynin Transdermal drug delivery system for oxybutynin |
| 05/13/2004 | DE10250646A1 Cosmetic and/or pharmaceutical hair treatment compositions, especially for promoting hair growth, containing melatonin (or derivative) and Gingko biloba and biotin as potentiating agents |
| 05/13/2004 | DE10250215A1 Wart removal device comprises a cover element which does not let through air, carries a material containing an active agent, and is provided with an adhesive layer compatible with human skin |
| 05/13/2004 | DE10250081A1 Wasserlösliche Meloxicam Granulate Water soluble meloxicam granules |
| 05/13/2004 | DE10249890A1 Gallensäurekonjugate und damit gebildete Partikel Gallensäurekonjugate and thus formed particles |
| 05/13/2004 | DE10249853A1 Flexible, plaster-type chip heating system, for thermodynamic control of topical (trans)dermal systems, including supporting matrix, electrical energy source, controlling microprocessor and electric heater |
| 05/13/2004 | DE10249401A1 Liposomen formende Zusammensetzung Liposome-forming composition |
| 05/13/2004 | CA2543370A1 Formulations for topical delivery of bioactive substances and methods for their use |
| 05/13/2004 | CA2504361A1 Formulations containing melatonin, ginkgo biloba, and biotin |
| 05/13/2004 | CA2504341A1 Melatonin daily dosing units |
| 05/13/2004 | CA2503841A1 Therapeutic compositions |
| 05/13/2004 | CA2503381A1 Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| 05/13/2004 | CA2503121A1 Pulsatile release compositions of milnacipran |
| 05/13/2004 | CA2502378A1 Stabilized, solid-state polypeptide particles |
| 05/13/2004 | CA2501701A1 Chemotherapeutic agent-incorporated pharmaceutical preparation |
| 05/12/2004 | EP1418228A1 Macroencapsulated secretory cells |
| 05/12/2004 | EP1417976A1 Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect |
| 05/12/2004 | EP1417975A1 REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT |
| 05/12/2004 | EP1417972A1 Stabilized teriparatide solutions |
| 05/12/2004 | EP1417970A2 Anti-allergic, anti-bacteric and anti-redden compound for eyes |
| 05/12/2004 | EP1417960A1 Sustained release micropellets and process for producing the same |
| 05/12/2004 | EP1417959A1 Tablet for buccal, sublingual or gingival administration, comprising an effervescent couple |
| 05/12/2004 | EP1417958A1 Wet granulation process |
| 05/12/2004 | EP1417895A1 Quick water-dissolving film containing cosmetic, aromatic, pharmaceutical or food substances and process for making the same |
| 05/12/2004 | EP1417487A2 Epitope testing using hla |
| 05/12/2004 | EP1417239A1 Regioselectively reticulated polysaccharides |
| 05/12/2004 | EP1417236A2 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 05/12/2004 | EP1417226A1 Derp1 and proderp1 allergen derivatives |
| 05/12/2004 | EP1417172A1 Process for the preparation of amorphous form of torsemide |
| 05/12/2004 | EP1416990A1 Inhalation device with a pharmaceutical composition |
| 05/12/2004 | EP1416974A1 Gas microsphere liposome composites |
| 05/12/2004 | EP1416966A2 Methods for treating joint inflammation, pain, and loss of mobility |
| 05/12/2004 | EP1416938A1 Delayed and sustained drug release |
| 05/12/2004 | EP1416926A2 Zinc containing compositions for anti-viral use |
| 05/12/2004 | EP1416922A1 Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 05/12/2004 | EP1416921A2 Once-a-day oxycodone formulations |
| 05/12/2004 | EP1416920A2 Multiplex drug delivery system suitable for oral administration |
| 05/12/2004 | EP1416919A1 Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate |
| 05/12/2004 | EP1416918A1 Synergistic filler composition |
| 05/12/2004 | EP1416917A1 Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct) |
| 05/12/2004 | EP1416916A1 Chitin microparticles and their medical uses |
| 05/12/2004 | EP1416915A1 Enhanced pharmacokinetic profile of hydrophobic substances |
| 05/12/2004 | EP1416914A1 Expandable gastric retention device |
| 05/12/2004 | EP1416907A1 Topical composition for follicular delivery of an ornithine decarboxylase inhibitor |
| 05/12/2004 | EP1416842A2 Pharmaceutical combinations of oxycodone and naloxone |
| 05/12/2004 | EP1383464A4 Nail compositions and methods of administering same |
| 05/12/2004 | EP1341785A4 HYDROLYSIS OF R(R*,R*)]-2-(4-FLUOROPHENYL)-$g(b),$g(d) -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4- (PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE |
| 05/12/2004 | EP1339378A4 Use of cyclosporin a 7-thioamide derivatives for hair growth |
| 05/12/2004 | EP1330250B1 Rapidly disintegrating sustained release cefuroxime axetil composition |
| 05/12/2004 | EP1309352B1 Antifungal ketoconazole composition for topical use |
| 05/12/2004 | EP1292303B1 A stable pharmaceutical formulation comprising torsemide modification ii |
| 05/12/2004 | EP1226267B1 Process for producing a product containing antihypertensive tripeptides |
| 05/12/2004 | EP1171124A4 Anthelmintic compositions |
| 05/12/2004 | EP1161410B1 Retinoid antagonists and use thereof |
| 05/12/2004 | EP1154778B1 Pharmaceutical preparation containing dithranol |
| 05/12/2004 | EP1152753B1 Combinations of formoterol and fluticasone propionate for asthma |
| 05/12/2004 | EP1151756A4 Application of polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of oncological diseases and the diabetes mellitus |
| 05/12/2004 | EP1146863B1 Lyophilisates with improved reconstitutibility |